Daunorubicin hydrochloride and Venoocclusive liver disease - a phase IV clinical study of FDA data

Summary:

We study 1,469 people who have side effects when taking Daunorubicin hydrochloride. Venoocclusive liver disease is found, especially among people who are female, 60+ old, have been taking the drug for < 1 month, also take Mylotarg and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people take Daunorubicin hydrochloride and have Venoocclusive liver disease. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 28, 2023

1,469 people reported to have side effects when taking Daunorubicin hydrochloride.
Among them, 22 people (1.5%) have Venoocclusive liver disease.

What is Daunorubicin hydrochloride?

Daunorubicin hydrochloride has active ingredients of daunorubicin hydrochloride. Currently, eHealthMe is studying from 1,474 Daunorubicin hydrochloride users.

What is Venoocclusive liver disease?

Venoocclusive liver disease (small veins in the liver are obstructed) is found to be associated with 611 drugs and 365 conditions by eHealthMe. Currently, we are studying 6,265 people who have Venoocclusive liver disease.

Number of Daunorubicin hydrochloride and Venoocclusive liver disease reports submitted per year:

Could Daunorubicin hydrochloride cause Venoocclusive liver disease?

Time on Daunorubicin hydrochloride when people have Venoocclusive liver disease *:

Gender of people who have Venoocclusive liver disease when taking Daunorubicin hydrochloride *:

female: 66.67 %
male: 33.33 %

Age of people who have Venoocclusive liver disease when taking Daunorubicin hydrochloride *:

Common drugs people take besides Daunorubicin hydrochloride *:

Common side effects people have besides Venoocclusive liver disease *:

Thrombocytopenia (decrease of platelets in blood): 9 people, 40.91%
Febrile Neutropenia (fever with reduced white blood cells): 9 people, 40.91%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 5 people, 22.73%
Cerebral Haemorrhage (bleeding within the brain): 5 people, 22.73%
Muscle Aches (muscle pain): 5 people, 22.73%
Drug Resistance (reduction in effectiveness of a drug): 5 people, 22.73%
Hypersensitivity: 5 people, 22.73%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 22.73%
Renal Impairment (severely reduced kidney function): 4 people, 18.18%
Pleural Effusion (water on the lungs): 4 people, 18.18%

Common conditions people have *:

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 11 people, 50.00%
Bone Marrow Conditioning Regimen: 6 people, 27.27%
Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 6 people, 27.27%
Alloimmunisation (alloimmunity is an immune response to foreign antigens (alloantigens) from members of the same species): 4 people, 18.18%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 13.64%
Venoocclusive Disease (small veins in the liver are obstructed): 1 person, 4.55%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 1 person, 4.55%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Daunorubicin hydrochloride and have Venoocclusive liver disease?

Check whether Venoocclusive liver disease is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Daunorubicin hydrochloride side effects by duration, gender and age:

Daunorubicin hydrochloride side effects (1,474 reports)

Venoocclusive liver disease treatments and more:

Venoocclusive liver disease (6,265 reports)

Common drugs associated with Venoocclusive liver disease:

All the drugs that are associated with Venoocclusive liver disease:

Venoocclusive liver disease (611 drugs)

Common conditions associated with Venoocclusive liver disease:

All the conditions that are associated with Venoocclusive liver disease:

Venoocclusive liver disease (365 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on daunorubicin hydrochloride (the active ingredients of Daunorubicin hydrochloride) and Daunorubicin hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.